argenx's acquisition of Unnatural Products adds macrocyclic peptides that could yield oral or long-acting treatments for immune-mediated diseases.
|Articles|September 8, 2014
University of Toronto Announces Collaboration with Janssen and Johnson & Johnson Innovation
Author(s)BioPharm International Editors
Three-year agreement will support research on treatments for major brain disorders in Neuroscience Catalyst project.
Advertisement
The University of Toronto announced on Sept. 8, 2014 a open innovation collaboration with Janssen facilitated by the J&J Innovation center of California that will support research through the Collaborative Center for Drug Research (CCDR). The three-year agreement will help identify and validate new therapeutic targets that could advance clinical treatment for major brain disorders, including mood disorders and Alzheimer’s disease.
The partnership is intended to enhance discovery and exploration in the field of neuroscience and mental health. Under the terms of the agreement, the CCDR will issue three calls for proposals over three years. Collaborative and open-source research projects will be solicited from researchers at the University of Toronto and its affiliated hospitals through the Toronto Academic Health Science Network. Scientists from Janssen will work with university researchers to provide the drug discovery expertise required to rapidly develop new medicines from basic science innovations.
Source:
Advertisement
Related to this article
A single subcutaneous dose of Janux’s CD19-targeted T-cell engager JANX011 depleted more than 90% of B cells in three of five healthy volunteers at the top dose, with only Grade 1 cytokine release syndrome. Patient studies in immune thrombocytopenia and rheumatoid arthritis are planned for 2027.
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
In a phase 1 study, Johnson & Johnson’s combination of pasritamig and JNJ-9401, two bispecific antibodies targeting KLK2 and PSMA, cut PSA by at least 50% in 73% of patients with metastatic castration-resistant prostate cancer. The regimen is now in phase 3.
A real-world study found evolocumab cut fatal or nonfatal heart attack risk 20% vs ezetimibe in adults with ASCVD and prior statin use.
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Johnson & Johnson's amivantamab (Rybrevant Faspro) won accelerated FDA approval for pretreated recurrent head and neck cancer.
Oxford spinout Alethio Therapeutics closed a $90 million Series A to take ATX-011, a monoclonal antibody against the G6B receptor, into Phase 1/2a studies in essential thrombocythemia. It is also developing a G6B-targeted ADC for myelofibrosis.
Advertisement
Advertisement
Trending on BioPharm International
1
Amgen Real-World Study Links Evolocumab to Lower Heart Attack Risk Than Ezetimibe
2
FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer
3
T-Therapeutics Raises $133 Million to Take TCR Bispecifics Into the Clinic
4
Alethio Raises $90 Million to Advance First-in-Class G6B Antibody for Essential Thrombocythemia
5